Tumor Assessments: Tumor assessments will include all known or suspected disease sites. Imaging may include chest, abdomen and pelvis CT or MRI s cans, and bone scans. CT or MRI scans, as well as bone scans, when indicated, are to be done every 12 weeks (±5 days) or when if clinically in dicated until disease progression that requires new treatment modality, permanent discontinuation, or death. Disease progression will be confirmed with two consecutive timepo ints at least 4-8 weeks apart in the absence of rapid clinical deterioration. 18. Serious and Non-serious Adverse Event Monitoring: Adverse events should be documented and recorded at each visit using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTC AE) version 5.0. Participants must be followed for AEs for 6 months after the last study treatment administration or until all drug related toxicities have resolved, whichever is later; or earlier than 6 months should the participant commence another anticancer therapy in the meantime. The time period for actively eliciting and collecting AEs and SAEs (“active collection period”) for each participant begins from the tim e the participant provides informed consent through and including 6 months after the last study treatment administration or until all drug related toxicities have resolved, whichever is later. If the participant begins a new anticancer therapy, the period for recording non-serious AEs on the CRF ends at the time the new treatment is started. How ever, any SAEs occurring during the active collection period must still be reported to Pfizer Safety and recorded on the CRF, irrespective of any intervening treatment. 19. Concomitant Treatments: All concomitant medications and non-drug supportive interventions should be recorded in the CRF.CCI PF-06936308 C3621001 Final Protocol Amendment 2, 22 Dec 2020 PFIZER CONFIDENTIAL Page 25Schedule of Study Treatment, Pharmacokinetics, Tremelimumab and Sasanlimab Immunogenicity Asse ssments (Part 1) Protocol Activity Screen (£28 days)Treat ment Period Post Treat ment Cycle 1 Cycle 2 End of Treat mentFollow -Up (Months after EOT visit) Study Day Day 1Day 3 -6Day 8Day 15 Day 22 Day 29 Day 43 Day 57 Day 71 Day 85 Day 113M1 M2 M4 M6 Cycle Day Day 1Day 29Day 57Day 85Day 9928-35 days Visit Window (hours)±24 hr ±48 hr ±48 hr Visit Window (days)±2 ±4 ±2 ±4 ±2 ±2 ±2 ±2 ±2 ±4 ±4 ±4 ±4 Study Treat ment AdC681–all participantsX X pDNA2–all participantsX X X X X X Tremelimu mab3– for cohorts assigned to receive tremelimumabX X X X X X X X Sasanlimab 4–for cohorts assigned to receive sasanlimabX X X X X X X X Pharmacokinetic s Immunogenicity PK for tremelimumab5X X6X6X6X6 X X X X X X X X X ADA for tremelimumab5X X X X X X X X PK for sasanlimab6X X8X8X8X8X X X X X X X X X ADA forsa sanlimab7X X X X X X X X PF-06936308 C3621001 Final Protocol Amendment 2, 22 Dec 2020 PFIZER CONFIDENTIAL Page 26Protocol Activity Screen (£28 days)Treat ment Period Post Treat ment Cycle 1 Cycle 2 End of Treat mentFollow -Up (Months after EOT visit) Study Day Day 1Day 3 -6Day 8Day 15 Day 22 Day 29 Day 43 Day 57 Day 71 Day 85 Day 113M1 M2 M4 M6 Cycle Day Day 1Day 29Day 57Day 85Day 9928-35 days Visit Window (hours)±24 hr ±48 hr ±48 hr Visit Window (days)±2 ±4 ±2 ±4 ±2 ±2 ±2 ±2 ±2 ±4 ±4 ±4 ±4 Study Treat ment Abbreviations: ADA = Anti -drug antibody; Adenovirus (AdC68); EOT = End of Treatment; pDNA = Plasmid deoxyribonucleic acid, PK = Pharmacokinetics 1. Adenovirus (AdC68) will be administered intramuscularly on Cycle 1 Day 1 and Cycle 2 Day 1. Tremelimumab and sa sanlimab will be administered after the adenovirus for participants assigned to receive these components. 2. Plasmid DNA (pDNA) vaccinations will be administered intramuscularly using an electroporation device on Day 29, Day 57 and Day 85 of each cycle. Tremelimumab and sasanlimab will be administered after the pDNA for participants assigned to receive these components. All pDNA vaccinations should be administered prior to administering the tremelimumab and sasanlimab. 3. Tremelimumab will be administered s ubcutaneously in close proximity to the vaccine injected muscle and vaccine draining lymph nodes on Day 1, Day 29, Day 57 and Day 85 of each cycle. Tremelimumab will be administered after the adenovirus or pDNA and, for participants assigned to receive s asanlimab, before the sasanlimab. Both tremelimumab injections should be administered prior to administering the sasanlimab. 4. Sasanlimab will be administered subcutaneously in close proximity to the vaccine injected muscle and vaccine draining lymph n odes o n Day 1, Day 29, Day 57 and Day 85 of each cycle. Sasanlimab will be administered after the adenovirus or pDNA and after the tremelimumab. 5. Blood samples for determination of tremelimumab drug concentrations and for detection of ADA/NAb against tremelimuma b will be collected as outlined in the schedule of activities . Samples to be collected on dosing days are to be obtained within 6 hours prior to tremelimumab dosing. 6. For participants assigned to Cohorts 3A, 6A, and 7A only. 7. Blood samples for determination of sasanlimab drug concentrations and for detection of ADA/NAb against sasanlimab will be collected as outlined in the schedule of activities . Samples to be collected on dosing days are to be obtai ned within 6 hours prior to sasanlimab dosing. 8. For participants assigned to Cohorts 4A and 5A only. PF-06936308 C3621001Final Protocol Amendment 2, 22 Dec 2020 PFIZER CONFIDENTIAL Page 27SCHEDULE OF ACTIVITIES FOR DOSE EXPANSION (PART 2) Protocol Activity Screen 1 (≤28 days)Treatment Period Post Treatment Cycle 1 Cycle 2 End of Treatment 32Follow- Up (Months after EOT visit)Survival Follow-up34 Study Day Day 1Day 8Day 15Day 22Day 29Day 43Day 57Day 71Day 85Day 113Month 133Month 2 Month 4 Month 6 Post 6-Month Follow-up Cycle Day Day 1Day 29Day 57Day 85Day 9928 to 35 daysEvery 3 Months Visit Window (Days) *±1±2 ±2 ±2 ±4 ±2 ±4 ±2 ±2 ±2 ±2 ±2 ±4 ±4 ±4 ±4 ±10 Informed consent2X Tumor histor y3X Medical histor y7X Complete physical examination8XX Abbreviated physical examination8XXXXX X X X X X X X X Assessment of skin thickness at administration sites9X Height X Weight X X X X Vital signs10X XXXXX X XXXXX X X X X X Performance status11XX X X X X X X X X X X X X Laboratory Unique Screening Labs12X Hematolog y13X XXXXXXXXXXXXXX X X X X X Blood Chemistr y14X XXXXXXXXXXXXXX X X X X X Coagulation15XX X X X X XCCI PF-06936308 C3621001Final Protocol Amendment 2, 22 Dec 2020 PFIZER CONFIDENTIAL Page 28Protocol Activity Screen 1 (≤28 days)Treatment Period Post Treatment Cycle 1 Cycle 2 End of Treatment 32Follow- Up (Months after EOT visit)Survival Follow-up34 Study Day Day 1Day 8Day 15Day 22Day 29Day 43Day 57Day 71Day 85Day 113Month 133Month 2 Month 4 Month 6 Post 6-Month Follow-up Cycle Day Day 1Day 29Day 57Day 85Day 9928 to 35 daysEvery 3 Months Visit Window (Days) *±1±2 ±2 ±2 ±4 ±2 ±4 ±2 ±2 ±2 ±2 ±2 ±4 ±4 ±4 ±4 ±10 Cardiac Troponin-I (cTnI)16XX X X X Urinalysis17XX X X X X X X X X X Pregnancy Test or FSH Level (Serum) 18XX X X X X X X X X X Contraception Check19XX X X X X X X X X X X X X (12 lead) ECG20XX X X X X X Registration Registration21X Study Treatment Adenovirus (AdC68) administration 22 Refer to Part 2 Schedule of Study Treatment, Pharmacokinetics and Immunogenicity Assessments Plasmid DNA (pDNA) administration 22 Tremelimumab administration 22 Sasanlimab administration 22 Tumor Assessment CT scan, MRI scan or bone scan 23X Performed every 8 weeks up to Week 3223(X) Other samplings AChR antibod y25XCCI PF-06936308 C3621001Final Protocol Amendment 2, 22 Dec 2020 PFIZER CONFIDENTIAL Page 29Protocol Activity Screen 1 (≤28 days)Treatment Period Post Treatment Cycle 1 Cycle 2 End of Treatment 32Follow- Up (Months after EOT visit)Survival Follow-up34 Study Day Day 1Day 8Day 15Day 22Day 29Day 43Day 57Day 71Day 85Day 113Month 133Month 2 Month 4 Month 6 Post 6-Month Follow-up Cycle Day Day 1Day 29Day 57Day 85Day 9928 to 35 daysEvery 3 Months Visit Window (Days) *±1±2 ±2 ±2 ±4 ±2 ±4 ±2 ±2 ±2 ±2 ±2 ±4 ±4 ±4 ±4 ±10 Pharmacokinetics and Tremelimumab ADARefer to Part 2 Schedule of Study Treatment, Pharmacokinetics and Immunogenicity Assessments Pharmacokinetics and Sasanlimab ADA Other clinical assessments Serious and non-serious adverse event monitoring 30X Concomitant medications and non-drug supportive interventions 31XXXXXXXXXXXXX X X X X X X Survival Follow-up34X * Visit windows during the treatment period are to be calculated based on the previous dosing visit. Abbreviations : Ĭ= ongoing; AChR = acetylcholine receptor; ADA = anti-drug antibodies; AdC68= Adenovirus; AE = adverse events; CRP= C-Reactive P rotein; CT = computed tomography; ECG = electrocardiogram ;EOT = End of Treatment; ER = estrogen receptors; HER2 = human epidermal growth factor receptor 2; hsCRP=high sensitivity C-reactive protein; MRI = magnetic resonance imaging; MSLN = mesothelin; MUGA = multiga ted acquisition scan; PBMC = peripheral blood mononuclear cell; pDNA=plasmid deoxyribonucleic acid; PR = progesterone receptors; (X)=Optional CCI CCI PF-06936308 C3621001Final Protocol Amendment 2, 22 Dec 2020 PFIZER CONFIDENTIAL Page 30Protocol Activity Screen 1 (≤≤28 days)Treatment Period Post Treatment Cycle 1 Cycle 2 End of Treatment 32Follow- Up (Months after EOT visit)Survival Follow-up34 Study Day Day 1Day 8Day 15Day 22Day 29Day 43Day 57Day 71Day 85Day 113Month 133Month 2 Month 4 Month 6 Post 6-Month Follow-up Cycle Day Day 1Day 29Day 57Day 85Day 9928 to 35 daysEvery 3 Months Visit Window (Days) *±±1±2 ±2 ±2 ±4 ±2 ±4 ±2 ±2 ±2 ±2 ±2 ±4 ±4 ±4 ±4 ±10 1. Screening: To be obtained within 28 days prior to study entry.